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1  | INTRODUCTION
Rare bleeding disorders (RBD) account for 3%- 5% of all inherited co-
agulation factor deficiencies, including deficiencies of coagulation fac-
tors I (fibrinogen), factor (F) II, FV, combined FV and FVIII, FVII, FX, 
FXI, FXIII and congenital deficiency of vitamin K- dependent clotting 
factors (VKCFD). These disorders most often inherited in autosomal 
recessive manner, except for some cases of FXI deficiency (FXID) and 
FID. Prevalence of RBD varies from 1 per 300 000 to 500 000 for 
FVIID to 1 per 2 million for FXIIID and FIID.1 Bleeding tendency sig-
nificantly varies between these disorders, and most patients with com-
bined FV- FVIIID (CFV- VIIID) and FVD have mild bleeding and patients 
with FXID bleeds only after trauma or surgery but most patients with 
FXIIID have severe life- threatening bleeding.2,3 Intracranial haemor-
rhage (ICH) as the most dreadful and the main cause of death among 
patients with RBD is commonly observed in congenital FXIIID. About 
one- third of these patients without appropriate prophylaxis treatment 
experience this diathesis.4 ICH was less frequently reported in FVIID, 
FID and FXD, and rarely was observed in FIID and FVD.5 Although ICH 
is the main cause of morbidity and mortality, timely diagnosis and ap-
propriate management of these bleeding disorders can significantly re-
duce the rate of ICH and related adverse consequences.4,5 In severely 
affected patients with RBD, ICH most often spontaneously occurred 
early in life. This presentation can occur intrauterine, immediately after 
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Abstract
Intracranial haemorrhage (ICH) is the most dreadful complication, and the main cause 
of death among patients with rare bleeding disorders (RBD) and prenatal diagnosis 
(PND) is a preventative lifesaving program. A total of 39 PNDs were reported in the 
literature through a search on PubMed, EMBASE, SCOPUS and Web of Science da-
tabases, most often for congenital factor (F) XIII and FVII deficiencies and rarely in 
FX, FV deficiencies and afibrinogenemia. The main cause to request a PND is ICH and 
related morbidity and mortality. Different molecular methods including direct se-
quencing and linkage analysis as well as polymerase chain reaction- restriction frag-
ment length polymorphism (PCR- RFLP) for a specific mutation are the most common 
used methods for PND, while factor assay and combination of molecular and factor 
assay also were used. In this research, 7 severely affected foetuses were identified 
during PND including 3 foetuses with FXIII deficiency, 3 with FVII deficiency and 1 
with FX deficiency. Out of these 7 cases, intrauterine ICH occurred in 1 case with 
FXIII deficiency, 1 was electively aborted and 1 case with severe FVII deficiency re-
ceived intrauterine factor transfusion. Postdelivery ICH was reported for 1 patient 
with severe FVII deficiency within the first month of life. All other pregnancies were 
uneventful.
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birth or during labour due to the stressful condition of delivery.2,6-9 
For such families, prenatal diagnosis (PND) can be a lifesaving diag-
nostic protocol, which leads to a timely diagnosis, suitable precautions 
and appropriate management of patients with RBD and high- risk life- 
threatening bleeding. Here, available data about PND in RBD were 
reviewed to make a primary background in this setting.
2  | STRATEGY OF SEARCH
In this study, data were obtained from previous studies. As there were 
a few studies in this area, the reports were found easily. A research 
was performed on databases of PubMed, EMBASE, SCOPUS and Web 
of Science during 1980 to 2017. The search terms included the combi-
nation of prenatal diagnosis or PND with rare bleeding disorder/RBD, 
factor I/FI/fibrinogen deficiency, factor II/FII/F2 deficiency, factor V/
FV/F5 deficiency, combined factor V and factor VIII/FV and FVIII/ 
F5 and F8 deficiency, factor VII/ FVII/F7 deficiency, factor X/FX/F10 
deficiency, factor XI/ FXI /F11 deficiency, factor XIII/FXIII/F13 defi-
ciency. In addition, the references to all retrieved studies were evalu-
ated in order to find potentially relevant reports.
3  | RESULTS
3.1 | Selected studies
In the present research, 361 studies were found in initial search and 
89 articles were excluded due to duplication. The abstracts of all re-
maining papers were carefully assessed, and 251 further articles were 
excluded due to different reasons including PND of common bleeding 
F IGURE  1 Flow chart of systemic 
review [Colour figure can be viewed at 
wileyonlinelibrary.com]
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disorders, PND of unrelated disorders, review articles, guidelines and 
non- English articles. By careful screening of all 21 remain studies, 4 
more articles about PND of other inherited bleeding disorders were 
excluded. Finally, by the exclusion of inappropriate papers for this 
study, 17 studies were selected (Figure 1).
3.2 | Prenatal diagnosis in rare bleeding disorders
In the literature, PND was performed for afibrinogenemia, FVD, FVIID, 
FXD and FXIIID. A total of 39 PNDs were performed, most commonly 
for FXIIID (n: 17, 43.6%) and FVIID (n: 12, 30.8%).
For PND, different methods were used including molecular meth-
ods (n: 29, 74.4%), factor assay (n: 8, 20.5%) and simultaneous use 
of both methods (n: 2, 5.1%). More employed methods included di-
rect sequencing (n: 16, 41%), direct sequencing plus linkage analysis 
(n: 3, 7.7%), direct sequencing plus factor assay (n: 2, 5.1%), factor 
assay (n: 8, 20.5%), linkage analysis (n: 1, 2.6%), polymerase chain 
reaction- restriction fragment length polymorphism (PCR- RFLP) plus 
linkage analysis (n: 1, 2.6%) and PCR- RFLP for a specific mutation 
(n: 8, 20.5%). Factor assay was used more commonly in FXD (50% of 
cases with FXD), and only was performed for 3 and 1 patients of FVD 
and FXIIID, respectively. Linkage analysis, as the only diagnostic test, 
was performed in 1 case with FXIIID (6.6%). In Iran, a unique mutation 
was only used to screen FXIIID and all suspected cases using PCR- 
RFLP technique (p.Trp187Arg, c.559T>C), a relatively similar feature 
was reported for FVIID in some relatives in Lebanon with c.291+1G>C 
mutation. In all other cases with direct sequencing, a specific mutation, 
which was determined by whole exon sequencing of affected gene in 
foetus’s family, was used for PND.
Among 39 foetuses with PND, 7 of them (18%) (homozygotes: 3, 
compound heterozygotes: 2, very low factor level: 2) had severe fac-
tor deficiency, 19 (48.7%) were heterozygotes and 13 (33.3%) were 
normal. Besides, 6 of foetuses had severe factor deficiency and 3 
had congenital FXIIID. In the first case, parents decided to terminate 
the pregnancy, in the second case, they experienced foetal ICH and 
baby was born with hydrocephalus, and in the third case, data were 
not available. All other pregnancies were uneventful except for 1 pa-
tient with severe FVIID, who experienced ICH a few days postdelivery. 
Family history and details for 11 out of 39 cases were not available. 
All the remaining cases (n: 28) had an underlying congenital bleed-
ing disorder in their family history. The most common presentation 
led to request a PND was ICH (n: 16, 57.1%). ICH- related death was 
reported in 6 (21.4%) families, while in 4 (14.2%) cases, the causes of 
deaths were not specifically determined. The postcircumcision die also 
was reported in 1 (3.7%) case.
3.3 | Factor I deficiency
The only report of PND in afibrinogenemia was about a Palestinian 
family with 2 affected children and ICH occurrence after minor 
trauma. Direct sequencing of FGA and FGG genes failed to detect 
the underlying mutation, but in the DNA sequencing of FGB, a non-
sense mutation (p.Trp467Stop) was identified in homozygotes and T
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heterozygote states in affected siblings and parents, respectively. 
Amniocentesis was performed in the 16th week of gestation, and 
amniotic fluid cells were cultured and analysed to determine the un-
derlying mutation. In addition to direct mutation detection, micros-
atellite analysis of the FGA Intron 3 Tetranucleotide Repeat (FGAi3) 
was performed on the foetus and confirmed heterozygote state of 
the foetus (Table 1).10
3.4 | Factor V deficiency
Until now, only 3 cases of PND were performed for diagnosis of FVD 
in—foetal period, which 2 foetuses were unaffected and 1 was in the 
heterozygote state. In the first family, with a history of a child with 
homozygote FVD, who died due to ICH, PND was performed in next 
pregnancy and FV activity level of foetal was determined in the 22nd 
week of gestation and unaffected foetus was reported.11 In another 
study, first child of the family was diagnosed with FVD (FV activity: 
5%) due to dental postextraction bleeding. The child had no parental 
consanguinity, and his parents had no bleeding problem. In the sec-
ond pregnancy, the couple decided to undergo PND. The FV levels 
of mother and father were 63% and 49%, respectively. The first child 
was confirmed to be homozygous for G16088C missense mutation 
(p.Asp68His) in exon 3 of FV gene (F5), and his parents were het-
erozygous for this mutation. The factor level of the foetus was 15% 
(normal range at 22 weeks: 21%- 44%), and the foetus was also het-
erozygous for this mutation.12
The third family had a history of a child who suffered from severe 
recurrent nasal haemorrhage required blood transfusion. The FV ac-
tivity was 2%, and he was born from consanguineous marriage. In the 
second pregnancy, after consolation, the parents decided to undergo 
PND. Sequencing was shown the homozygous for C69969T (p.Gly-
2079Val) missense mutation. The parents were carrier for this muta-
tion. Mutation analysis and cord blood factor assay were performed on 
the foetus. The factor activity of foetus was 32%, which was in normal 
range (normal range at 22 weeks: 21%- 44%) and the mutation was not 
detected in the foetus (Table 1).12
3.5 | Factor VII deficiency
In the literature, there are only a few reports on PNDs in congenital 
FVIID. Almost all reports are about families with a positive family his-
tory of FVIID and ICH. In fact, like other RBD, the severity of disorder 
and history of ICH provoke parents to request a PND. In the first case, 
a family with congenital FVIID and history of a child with severe FVIID 
who died due to ICH at 4 months of life were reported. PND was 
performed in next pregnancy at the 24th week of gestation and FVII 
activity was 4%. In the 37th week of gestation, prenatal transfusion 
of FVII concentrate (200 IU) was performed 1 hour before caesarean 
that increased FVII activity to 100%. In this case, neonate was born 
with FVII activity of 75% and 6%, just after birth and 7 hours after 
birth, respectively.11 The second PND was reported in 1992. Parents 
were heterozygous for FVIID. They had 1 child with compound het-
erozygotes for 2 single nucleotide deletions in FVII gene (c.10698del T
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C and c.10785del C) that experienced ICH 2 times and once GI bleed-
ing; therefore, chorionic villus sampling was taken in the 10th week 
of gestation. The existence of 2 parental wild- type alleles indicated 
normal phenotype in PND study.13 Mcvey et al assessed parents 
with consanguinity and history of died girl due to cerebral haemor-
rhage and hydrocephaly. Both parents were heterozygote for FVIID. 
Therefore, PND was performed in next pregnancy and the boy was 
nonmutant for FVII gene mutation (IVS4+1G>A).14 In another study, 
FVII direct gene mutation detection and linkage analysis were used for 
PND and the unaffected foetus was reported.15 Ariffin et al reported a 
foetus with carrier parents for FVIID. They also had a history of 2 died 
children with FVIID and massive ICH. PND study indicated heterozy-
gote states of a foetus that was born with normal delivery without 
any complication.16 Mota et al, studied a family with FVIID and history 
of 2 died children with FVIID due to cerebral haemorrhage at age of 
5 weeks and 13 months, respectively. PND showed that the foetus 
was unaffected.17 Farah et al reported a 1- month age girl with FVIID 
who diagnosed with PND. The girl was received recombinant FVII as 
secondary prophylaxis after the occurrence of CNS bleeding. The girl 
was homozygote for c.291+1G>C mutation. Her parents were con-
sanguineous, and their child was born full term without any complica-
tion. Eight years later, in another study, Farah et al reported another 
PND analysis in which c.291+1G>C was used as a screening marker in 
2 close relative families.18,19 Shetty et al conducted a comprehensive 
study on a large number of families (n: 172) with haemophilia and RBD 
and an unaffected foetus in a family with FVIID was identified.20 The 
last report was performed by Peng et al. They assessed FVII underly-
ing gene mutation in proband and parents. Proband was homozygous 
for FVII c.572- 1G>A gene mutation and parents and foetus were het-
erozygote (Table 2).21
3.6 | Factor X deficiency
Only in 6 cases, PND has been used in FXD up to now, which 4 had 
a positive family history of FXD and the data of 2 families were not 
available. The first family had a child with prolonged postcircumcision 
bleeding, which managed with administration of fresh frozen plasma 
(FFP). Moreover, the child was also suffered from the intracerebral 
bleed. Laboratory assessments revealed that FX level was less than 
1%. Mutational analysis of proband and parents revealed that the 
proband inherited the loss of function mutation of his father. Despite 
the whole FX exon sequencing, no mutation was found in the mother. 
In the second pregnancy, the couple decided to undergo PND. The 
mutation analysis revealed that foetus did not inherit the mutation 
of the father but there was still 50% chance of being a carrier of FXD 
due to mother’s undetectable mutation. The foetus was born without 
complication, and the FX level was 36%. At age of 2 years, the FX 
level was 65%, which demonstrated the presence of a maternal muta-
tion and heterozygote status in the child. At third pregnancy, the cou-
ple again decided to request PND. Mutational analysis revealed that 
the foetus inherited paternal mutation and there was a 50% chance 
of being homozygous for FXD. As maternal mutation was undetect-
able, linkage analysis was performed and it was shown that the foetus T
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inherited the normal FX allele of the mother. Therefore, the foetus 
was heterozygote of FXD.22
The third family had a history of a child with severe FXD who ex-
perienced haemarthrosis. On the second pregnancy, they requested 
a PND. Accordingly, the foetal blood sample was taken and the FX 
level of the foetus was 21% (normal range at 18- 20 week of gestation: 
10.8%- 17.6%), which was unaffected.17 Sheety et al20 used factor 
assay for PND, and 2 unaffected foetuses were diagnosed.
The sixth family had a history of a child with haemarthrosis, mus-
cle bleeding and several mucosal bleeds, which was diagnosed at 17- 
month age. He was affected by the severe type of FXD. The second 
child was diagnosed with severe FXD in utero and coagulation studies 
in neonatal period. At age of 18 months, she was suffered from recur-
rent mucosal and joint bleeding which managed by FFP. The muta-
tional analysis showed that both children were double heterozygote 
(p.Glu16Lys and p.Val298Met) (Table 3).7
3.7 | Factor XIII deficiency
Prenatal diagnosis most commonly was used for FXIIID. In south-
east Iran, p.Trp187Arg mutation in exon 4, routinely was used for 
PND. Among 8 reported cases from this area, 1 was homozygotes 
that CT scan revealed intrauterine ICH and neonatal hydrocephalus. 
Although the mother underwent normal vaginal delivery, a neonate 
with hydrocephaly was born. Among these families, 3 of 8 had a 
history of CNS bleeding and 4 (50%) had a positive history of death 
due to congenital FXIIID.23 Short tandem repeat (STR) successfully 
was used in 2 studies for PND.24,25 Only in 1 case, FXIII assay was 
performed for PND, which FXIII level was below 5%. Therefore, 
parents decided to terminate the pregnancy.11 In a recent study, 
which was performed on Indian families, PND was conducted for 
5 families, and 5 different mutations in FXIII- A gene were detected 
(Table 4).26
4  | DISCUSSION
Intracranial haemorrhage is the most dreadful complication and the 
main cause of death among patients with RBD. This life- threatening 
diathesis has 2 main consequences including death or neurological 
complications.4 ICH and related morbidity and mortality are the main 
causes to request a PND for subsequent pregnancy.10 But other se-
vere bleeds are also led to undergo a PND. Due to the high rate of 
spontaneous ICH in congenital FXIIID, PND can be requested for any 
foetus suspected to severe congenital FXIIID. It is routinely performed 
in southeast Iran that presents the high rate of disorder.23 The fre-
quency of ICH is ranged from 0% for FXID to ~30% for FXIIID. PND 
was requested for those families with previous history of ICH. For 
FVD, even recurrent nasal bleeding led to a PND request. Although 
PND is useful in RBD, several issues should be considered before per-
forming. Accordingly, the healthcare services, which include a team 
of obstetrician, haematologist, paediatrician and clinical genetics ex-
pertise, provide multidisciplinary care for mothers and foetus. The 
aim of this service is to provide different aspects of obstetric man-
agement including preconceptual counselling, PND and post- PND 
cares.28 Preconceptual counselling, which should be precede PND, 
is the critical step that provides the information about the option of 
PND by considering the limitations and potential complications and 
also the bleeding risks to mother and foetus.28,29 The main advantage 
of PND is to minimize or prevent the life- threatening bleeds.2 In one 
of affected foetus with FXIIID, intrauterine ICH occurred and a foetus 
with hydrocephalus was born. Although foetal ICH is rare, it has been 
reported in congenital FVD, FVIID and FXD as well as classical hae-
mophilia.7,9 Therefore, for mothers with affected foetus and high risk 
of life- threatening bleeding, post- PND precautions should be consid-
ered.8 An important issue is that an affected foetus with high risk of 
life- threatening bleeding during pregnancy or labour has indication of 
intrauterine factor transfusion. This was performed for a foetus with 
severe FVIID, just before labour and delivery occurred without any 
abnormal bleeding.11 Although this case had good outcome, several 
foetuses with severe FVIID were delivered without such interven-
tion.1 But it should be considered that ICH during labour is a challenge 
in patients with high risk of ICH such as congenital FXIIID.2 Type of 
delivery is another crucial issue. This issue is investigated more fre-
quently in classical haemophilia and as a result, uncomplicated normal 
vaginal delivery is a better option.2,30,31 Generally, the rate of ICH in 
delivery with forceps, vacuum extraction, caesarian section during la-
bour and caesarian section before labour are 1 per 664, 860, 907 and 
2750, respectively.2,30,32 Based on the available experiences for PND 
in congenital bleeding disorders, even vaginal delivery lead to the oc-
currence of ICH in congenital FXIIID and a considerable number of 
these patients experience this diathesis during labour.1,2,23 Therefore, 
further studies are required to resolve this issue. Another very impor-
tant question is about postdelivery precautions. Although except in 
severe congenital FXIIID, there is no consensus about primary proph-
ylaxis in other RBD, it is recommended that patients with other RBD 
such as FXD, FVIID and afibrinogenemia with severe life- threatening 
bleeds consider the secondary prophylaxis. But sometimes lack of 
primary prophylaxis in these patients leads to fatal consequences; 
therefore, some experts consider primary prophylaxis for their high- 
risk patients.18,19 Even in cases with successful delivery subsequent 
to PND, life- threatening ICH occurred in the first days of life.2,4,18,19
Generally, PND is conducted in the first and the second trimes-
ters via testing of placental or amniotic fluid samples. These inva-
sive methods have 1% risk of miscarriage and provide an option of 
terminating the pregnancy in the women with the affected foetus. 
However, it is the rationale that women who prefer to continue their 
pregnancies be aware of the mutation status33 and delivery of an 
affected baby should take special consideration. Recently, PND is 
suggested in third- trimester amniocentesis (after 34 weeks of gesta-
tion) as an option to avoid the miscarriage, which results from early 
testing.28,33 Some studies suggested the late amniocentesis was a 
safe technique.33 However, because there is limited practical experi-
ence in PND of RBD, no established data are available for the safety 
and acceptability of third trimester PND. In addition, third- trimester 
amniocentesis has about 1% complications related to the procedure 
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including preterm delivery, rupture of membrane and infections. 
Moreover, there is a probability of failing to obtain a sample (about 
of 1%) and unexpected delivery before the PND, which result in 
further stress for the families and their foetus.28,34 Therefore, the 
decision about the time of PND should be made based on potential 
benefits, the risk of procedures, the mother statue and opinion of 
expertise.28
Although direct sequencing is the most common method for 
PND, it should be considered that due to the heterogeneous nature 
of mutations and the large size, and complexity of some coagulation 
factors genes, direct sequencing was not able to detect all muta-
tions. In ~5% patients with RBD, the underlying mutation is not de-
tectable, but new technologies such as next- generation sequencing 
(NGS) can improve this situation.1,5 In the present research, 1 of 39 
cases, underlying FX gene mutation, was not detectable and linkage 
analysis was applied as an alternative method.22 Due to insufficient 
and limited resources in developing countries and costly determi-
nation of direct mutation detection, this method is not practical. 
Indirect detection (linkage analysis) using informative polymorphic 
markers is an auxiliary technique for PND of RBD in developing 
countries.35 By considering the limitations of linkage analysis, the 
rate of misdiagnosis should be decreased. One of the limitations is 
to undergo the study of entire family of the patients for PND. The 
most serious problem with the linkage analysis is the possibility of 
recombination between linked markers and disease locus that can 
lead to misdiagnosis. To overcome this problem, the use of at least 
1 proximal and 1 distal flanking marker is suggested. Although this 
can minimize the risk of incorrect diagnosis, it is not applicable for 
all cases. Moreover, as the selection of informative markers may 
be time- consuming, it is better to select the markers before prena-
tal sampling.22 Preimplantation genetic diagnosis (PGD) is another 
technique, which can be used instead of PND. PGD uses the in vitro 
fertilization (IVF) to create and test each embryo to find the genetic 
defects related to RBD and consequently identify the unaffected 
embryo to transfer to utero.36 PGD is indicated in families who 
avoid using invasive methods and in countries, which pregnancy 
termination is not acceptable. However, this method is still chal-
lenging and has different limiting factors.28,36
Cordocentesis, which perform to determine the cord blood factor 
level from 18 weeks of gestation, is rarely used today. This method 
is used in countries, which genetic analysis is not available or in the 
situations that genetic testing does not give an informative result.29 In 
about one- fifth of cases, selected test for PND was factor assay, but 
whenever reliable molecular methods including direct sequencing are 
available, such assays are not recommended. In the cases that factor 
assay is used as a diagnostic test for PND, all the limitations should be 
considered. For such studies, the purity of foetal sample plays an im-
portant role and a diluted sample can affect the results of coagulation 
assays. To overcome this problem, several simple ways can be used. 
The first recommendation is that the foetus blood samples should be 
collected in smaller volumes in several separated aliquots, and the 
proportion of citrate sodium anticoagulant to blood sample should 
be kept constant. This can prevent dilution of foetus blood with an-
ticoagulant or amniotic fluid. It is observed that in the first tube, the 
level of a factor is false while in subsequent small samples of aliquots 
this problem is resolved. Another recommendation is multiple factor 
assays that use other coagulation factors as an indicator to find any 
contamination with maternal fluids.20 Another problem is that the co-
agulation system is not well developed in the parental period; there-
fore, the activity level of most of the coagulation factors is lower in 
this period compared with adults. In addition, due to the difficulties in 
the foetal blood samples obtaining, a few studies report the reference 
range for coagulation factor activity in the parental period. However, 
knowing about the reference range of coagulation factors in the foe-
tus is necessary to avoid the misdiagnoses (Table 5).37
Due to limited available studies and cases as a major limitation of 
the present study, it was challenging to propose the precise guideline. 
However, several important points should be considered in performing 
a PND. First, it should be considered that not all patients with RBD have 
an indication for PND. PND can be used for all patients with severe 
congenital FXIIID and for those other RBD with severe factor deficiency 
and history of life- threatening bleeds,23 because performing such an in-
vasive procedure with a risk of foetal loss, should offer more benefits 
than dangers. Moreover, limitations of available diagnostic tests should 
be considered. In the high- risk foetus, appropriate precautions also 
should be considered, during pregnancy, within labour and postdelivery, 
Factors 
activity level
Gestation age (weeks)
19- 23 24- 29 30- 38 Newborns
FI (g/L, 
Clauses)
0.85 (0.57- 1.50) 1.12 (0.65- 1.65) 1.35 (1.25- 1.65) 1.68 (0.95- 2.45)
FII 16.9 (10- 24) 19.9 (11- 30) 27.9 (15- 50) 43.5 (27- 64)
FV 32.1 (21- 44) 36.8 (25- 50) 48.9 (23- 70) 89.9 (50- 140)
FVll 27.4 (17- 37) 33.8 (18- 48) 45.9 (31- 62) 52.5 (28- 78)
FX 20.5 (14- 29) 24.9 (16- 35) 28.0 (16- 36) 39.6 (21- 65)
FXl 13.2 (8- 19) 12.1 (6- 22) 14.8 (6- 26) 37.2 (13- 62)
FI, factor I.
Values are reported as mean, followed by parenthesis including lower and upper boundaries of 95% of 
the population.
TABLE  5 Coagulation factor activity (%) 
of foetus and newborn
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to choose an appropriate therapeutic regimen. By regarding these is-
sues, PND can be a lifesaving procedure for high- risk families.
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